Genentech Signs Up Sosei Heptares GPCR Smarts For $1bn+ Deal

The companies have agreed to a multi-year, multi-target research collaboration and license deal to discover and develop medicines that modulate GPCR targets across a range of diseases.

Researcher working with DNA on blurred background.
• Source: Shutterstock

Genentech Inc. has turned to Sosei Heptares  to help it to discover and develop medicines that are capable of modulating G protein-coupled receptors (GPCRs), a very large and diverse gene family with a lot of promising drug targets within it. Under the terms of the deal, the collaboration will combine Sosei Heptares’ GPCR-focused structure-based drug design capabilities with Genentech’s discovery, development and therapeutic are expertise directed towards multiple Genentech-nomimated GPCR targets. Genentech will be responsible for developing and commercializing potential new medicines for each novel target and will have exclusive global rights to them.

“In the partnership, we expect to apply our StaR platform to targets they have selected and take the initial DNA,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

Sino Biopharm Scoops LaNova In Chinese Pharma’s Biggest Biotech Buyout So Far

 

Sino Biopharm will pay almost $1bn to acquire what target LaNova’s CEO described as an “exploding” pipeline, which includes six clinical-stage candidates in the oncology area.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.

Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab

 

Plus deals involving Novartis/Sironax, Neuraxpharm/Dizlin, Recursion/RallyBio, MaaT/Clinigen, Future Pak/Theratechnologies, BerGenBio/Oncoinvent, Xoma/Turnstone and more.

China’s Mid-Cap Companies Thriving On Big Pharma Deals

 

Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.

More from Business

IPO Update: With Just Two Small Offerings In Q2, What’s Next?

 
• By 

With low valuations for biopharma companies that recently went public and little hope of a near-term turnaround as uncertainty lingers, IPO numbers may stay low for the rest of 2025.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.